Drug
Etanercept Via Autoinjector A
Etanercept Via Autoinjector A: highest development phase Post-Market, developed by Amgen. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Amgen
Trials
| Drug | Phase | Indication |
|---|---|---|
| Etanercept via Autoinjector A NCT01875991 | Post-Market | Rheumatoid Arthritis |
Latest
No recent events.
Follow Etanercept Via Autoinjector A on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.